Patents by Inventor Christine Landlinger

Christine Landlinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inhibiting C5a
    Patent number: 10344062
    Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X3)mKDX2QLGX1 (SEQ ID No. 99), wherein X1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X3 is (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X4 is VVASQLR (SEQ ID No.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: July 9, 2019
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Christine Landlinger, Frank Mattner
  • VACCINES AND MONOCLONAL ANTIBODIES TARGETING TRUNCATED VARIANTS OF OSTEOPONTIN AND USES THEREOF
    Publication number: 20170137509
    Abstract: The present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one isolated osteopontin peptide, as well methods for manufacturing said antibodies and vaccines. Furthermore, a diagnostic method making use of said antibodies is provided. Said antibodies and vaccines are used in therapy, especially in treatment and/or prevention of Type-2 diabetes and cardiovascular disease.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 18, 2017
    Applicant: AFFIRIS AG
    Inventors: Guenther STAFFLER, Christine LANDLINGER, Marie LE BRAS
  • Methods for inhibiting C5a with C5a peptides coupled or fused to a carrier protein
    Patent number: 9457078
    Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 4, 2016
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Christine Landlinger, Frank Mattner
  • VACCINE
    Publication number: 20150166620
    Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X3)mKDX2QLGX1 (SEQ ID No. 99), wherein X1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X3 is (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X4 is VVASQLR (SEQ ID No.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 18, 2015
    Applicant: AFFIRIS AG
    Inventors: Guenther Staffler, Christine Landlinger, Frank Mattner
  • VACCINES BASED ON PEPTIDES OF THE COMPLEMENT PROTEIN C5A
    Publication number: 20130216565
    Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRAN-ISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).
    Type: Application
    Filed: December 21, 2011
    Publication date: August 22, 2013
    Applicant: Affiris AG
    Inventors: Guenther Staffler, Christine Landlinger, Frank Mattner